YILING PHARMACEUTICAL(SZ:002603) Shang Hai Zheng Quan Bao·2026-01-22 20:03Core Viewpoint - Shijiazhuang Yiling Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Yiling Wanzhou International Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing authorization of Benanluofen Injection, marking a significant milestone for the company in expanding its pharmaceutical product pipeline [1][2]. Group 1: Drug Approval Details - Benanluofen Injection is the first approved chemical patent new drug from Yiling Wanzhou, classified as a non-steroidal anti-inflammatory drug (NSAID) used for postoperative pain management in abdominal and thoracoscopic surgeries [3][4]. - The drug has been granted a registration certificate with the approval number H20260006, and it is produced by Hebei Kaiwei Pharmaceutical Co., Ltd. [2][3]. Group 2: Market Context and Impact - According to the National Bureau of Statistics, in 2024, there will be approximately 312 million inpatient admissions and 104 million surgical procedures in China, reflecting an 8% increase compared to 2023 [3]. - The approval of Benanluofen Injection provides a new treatment option for postoperative pain management, aligning with the guidelines from the Chinese Medical Association for perioperative pain management [4]. Group 3: Financial Outlook - For the fiscal year 2025, the company anticipates a positive net profit, indicating a turnaround from previous losses, driven by strategic market expansion and enhanced management practices [6][8]. - The company aims to achieve a recovery in revenue growth while implementing a comprehensive cost control system to improve profit margins [8].